Compare FWRD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | DCTH |
|---|---|---|
| Founded | 1981 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.4M | 363.5M |
| IPO Year | 2024 | 2015 |
| Metric | FWRD | DCTH |
|---|---|---|
| Price | $8.70 | $11.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $37.50 | $22.00 |
| AVG Volume (30 Days) | ★ 1.5M | 378.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.54 | ★ 107.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | $24.54 |
| Revenue Next Year | $6.66 | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.65 | $8.12 |
| 52 Week High | $32.47 | $18.23 |
| Indicator | FWRD | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 25.27 | 53.27 |
| Support Level | N/A | $10.17 |
| Resistance Level | $30.86 | $11.24 |
| Average True Range (ATR) | 1.49 | 0.56 |
| MACD | -1.22 | -0.02 |
| Stochastic Oscillator | 1.04 | 46.85 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.